Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
FDA Grants Fast Track to World’s First Therapy for Diffuse Gastric Cancer
Details : SIGX1094, an investigational small molecule and the first targeted drug candidate for diffuse gastric cancer, has received fast track designation from the FDA.
Product Name : SIGX1094
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 20, 2025
Organoid-AI Drug Candidate Doses First Patient in Diffuse Gastric Cancer
Details : Sigx1094 targets FAK and YAP, which are crucial for cancer cell survival and proliferation, sigx1094 aims to disrupt the cellular mechanisms that enable tumor growth and metastasis.
Product Name : SIGX1094
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2025
Lead Product(s) : sigx1094
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Signet Therapeutics Receives IND Approval for Targeted Therapy for Diffuse Gastric Cancer
Details : Sigx1094, an investigational small molecule and the first targeted drug candidate for diffuse gastric cancer, has received IND approval from the FDA.
Product Name : sigx1094
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2024
Lead Product(s) : sigx1094
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
